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List of abbreviations 
 
ADA American Diabetes Association 
AGE advanced glycation endproduct 
ANOVA analysis of variance 
ATP adenosine triphosphate 
CAT catalase 
CE cholesterolester 
CETP cholesterolester transfer protein 
CI confidence interval 
CT computer tomography 
CuZnSOD copper-zinc SOD 
DM diabetes mellitus 
ECG electrocardiogram 
FFA free fatty acid 
HbA1c glycated haemoglobin 
HDL high density lipoprotein 
HWE Hardy Weinberg equilibrium 
LCAT lecitin-cholesterol acyltransferase  
LDL low density lipoprotein 
MnSOD manganese SOD 
NCBI National Center for Biotechnology Information 
oxLDL oxidized LDL 
p38 MAPK p38 mitogen activated protein kinase 
PCR-RFLP polymerase chain reaction-restriction fragment lenght polymorphism 
PKC protein kinase C 
PON1 paraoxonase 1 
RAGE receptor for advanced glycation endproduct 
ROS reactive oxygen species 
SNP single nucleotide polymorphism 
SOD superoxide dismutase 
T1DM Type 1 diabetes mellitus 
T2DM Type 2 diabetes mellitus 
TBE tris borate EDTA buffer 
WHO World Health Organisation 
 4 
Introduction 
 
      It is a well-estabilished fact that diabetes mellitus is a risk factor 
for cardiovascular disease [1] which is leading cause of death in 
diabetic population [2]. It is also well-known fact that tight control of 
diabetes is effective in reducing vascular complications [3]. One of 
the principal pathways to develop vascular complications is the 
production of  ROS [4]. There are multiple sources of oxidative stress 
in diabetes including nonenzymatic and enzymatic pathways [5]. In 
the process of mitochondrial respiration, molecular oxygen is 
essential for the complete metabolism of glucose and other 
substrates during the production of ATP. During the course of normal 
oxidative phosphorylation between 0.4 and 4% of all oxygen 
consumed is converted into superoxide. While ROS are generated 
under physiological conditions [6], excess generation of ROS  has 
pathological consequences [7]. They can stimulate oxidation of LDL, 
forming ox-LDL, which is not recognized by the LDL receptor leading 
to foam cell formation [8]. ROS can activate formation of AGE [9], 
polyol pathway [10], hexosamine pathway and PKC [11], involved in 
pathogenesis of microvascular and macrovascular complications [12]. 
      There is considerable evidence that hyperglycemia causes 
many of the major complications of diabetes including  macro- and 
microvascular damage [13,14,15,16,17]. Oxidative stress resulting 
from increased production of ROS (or their inadequate removal) plays 
a key role in the pathogenesis of diabetic complications. 
      In vivo studies reveal that oxidative stress due to hyperglycaemia 
occurs before vascular complications become clinically evident 
[18,19,20,21,22,23,24,25,26, 27,28,30,31,32,33]. Hyperglycaemia 
regulates stress-activated signaling pathways including nuclear 
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factor-κB, p38 MAPK, NH2-terminal Jun kinases/stress-activated 
protein kinases (JNK/SAPK), AGE/ RAGE, and protein kinase C. 
      It still have to be elucidated the fact that  some patients with DM 
develope vascular complications but this cannot be seen in the other 
patients with the same duration of diabetes mellitus or level of  
disease control [34]. We have focused on genes coding leading 
antioxidative enzymes superoxide dismutase (SOD), catalase (CAT) 
and paraoxonase 1 (PON1). 
      Specifically, we have targered SNPs for their likely functional role: 
SOD1 +35A/C (rs2234694) which is located adjacent to a splice site 
(exon3/intron3 boundary), SOD2 Ala16Val (rs4880) which has been 
suggested to alter protein structure [35] and function (C/T substitution 
in exon 2, codon position 2, aminoacid position 16) and catalase -
21A/T (rs7943316) which is located in the promotor region just 
proximal to the start site. The molecular basis of the PON1 
polymorphisms is a missence mutation in the coding region of PON1, 
resulting in a glutamine (Q)/arginine (R) substitution at codon 192 
(rs662) [36]. PON1Q192 is more efficient at metabolizing oxidized 
HDL or LDL than PON1R192 [37]. Polymorphism at position 55 
Leu(L)/Met(M) (rs854560) has been associated with plasma PON1 
protein levels, with PON1M55 being associated with low plasma 
PON1 level. Polymorphisms in promotor region of PON1 have for the 
most part not been yet characterized, but may affect splicing activity, 
message stability or efficiency of polyadenylation. 
      Superoxide dismutase 1 (CuZnSOD, SOD1, EC 1.15.1.1) is one 
of the cellular defense systems for oxidative insults [38]. The increase 
of CuZnSOD expression in human smooth muscle cells protects 
against oxidant injury. OxLDL cause an increase in the DNA binding 
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activity of activator protein-1  and nuclear factor κB, which is inhibited 
by CuZn-SOD overexpression. 
      Superoxide dismutase 2 (MnSOD, SOD2, EC 1.15.1.1) is present 
in mitochondria.  C/T substitution (GCT/GTT) has been shown to 
change the structural conformation of the mitochondrial targeting 
sequence (MTS) of the enzyme. Associations have been found 
between the Ala16Val SNP and  human neurodegenerative disorders 
[39].  
      Catalase (CAT, EC 1.11.1.6) is present in the peroxisomes and 
exists as a dumbbell-shaped tetramer of four identical subunits. 
Several SNPs in the CAT gene have been reported, most of which 
are associated with acatalasaemia [40]. 
      Human serum paraoxonase (PON1, EC 3.1.8.1.), a 43-kDa 
protein, catalyses the hydrolysis of organophosphate esters, aromatic 
carboxylic acid esters, and carbamates [41]. PON1 is synthesized in 
the liver and is mainly associated with high-density lipoprotein (HDL) 
[42]. The enzyme decreases accumulation of the lipid peroxides in 
low-density lipoprotein (LDL) due to its ability to reduce 
hydroperoxides [43] and it attenuates biological effects of mildly 
oxidized LDL. 
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Aims 
      We have focused on genes encoding leading antioxidative 
enzymes superoxide dismutase (SOD), catalase (CAT) and 
paraoxonase 1 (PON1). These enzymes play key role in the 
pathogenesis of chronic complications of diabetes mellitus. One of 
the principal pathways to develop vascular complications is the 
production of  ROS. Etiology of the vascular damage in patients with 
diabetes mellitus is multifactorial with considerable interindividual 
variability and the influence of the genetic background. 
 
 
Hypothesis: 
 
• we have considered that escalated oxidative stress relate to the 
formation and development of chronic vascular changes in patients 
with diabetes mellitus. 
• we have also presumed that activity of ROS is involved in the 
development of both types of vascular complications in diabetes 
mellitus. 
• we have expected that displacement of the equilibrium among 
ROS production and removing is caused not only by hyperglycaemia 
but also by insufficiency of antioxidative defense system. It has been 
still elucidated which of them is primary event.  
• dysfunction of antioxidative enzymes may be caused not only 
secondarily by the hyperglycaemia (e.g. process of nonenzymatic 
glycation) but also in primary association with the presence of gene 
polymorphisms of antioxidative enzymes. 
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• it has been evidenced that some of studied polymorphisms may 
influence activity or concentration of the enzymes. We expected that 
minor SNP or mutations preferable cause alteration of the enzyme 
than play a protective role.  
• we suppose that studied candidate genes for macroangiopathy 
do not play a major role in the process of microangiopathy.  
 
Aims of research:  
 
• to analyse polymorphisms of candidate genes for chronic 
vascular complications in patients with diabetes mellitus – genes for  
PON1, SOD1, SOD2, CAT. 
• to study an association between gene polymorphisms of 
antioxidant enzymes and the presence of macroangiopathy or 
microangiopathy in patients with diabetes. 
• to determine enzyme activity of paraoxonase 1 and superoxide 
dismutase. 
• to investigate gene polymorphism influence on enzyme activity. 
• to study the correlation of polymorphisms with some laboratory 
parameters monitored in patients with diabetes. 
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Methods 
 
Subjects 
      Total of  120 T1DM, 306 T2DM  and  control group of 140 healthy 
subjects without family history of diabetes were examined in this 
study. Diagnosis of T1 and T2DM was based on WHO/ADA definition 
of diabetes (1999), healthy subject didn´t fulfile the criteria for this 
diagnosis. They were in good health and namely free of any co-
morbidities often associated with diabetes, especially with T2DM 
(hypertension, obesity, hyperlipoproteinemia) and other endocrine 
disorders. Microangiopathy was confirmed by ophthalmoscopy or by 
the presence of peripheral neuropathy (diagnose was based on 
clinical features and by physical examination by 10 g monofilament, 
tuning fork and biothesiometry) in 167 patients who did not have any 
evidence of macrovascular disease from the clinical picture (no 
history of angina pectoris, normal ECG records or normal 
coronarogram). In case of suspection on autonomic neuropathy made 
from physical examination (tachycardia recorded by ECG in resting 
state, systolic blood pressure reaction on orthostatism) patients were 
excluded from this group. 66 subjects had macrovascular 
complications manifested by ischemic heart disease (diagnosis was 
based on ECG or coronarography), ischemic disease of the lower 
limbs (diagnosis was based on angiography of lower limbs arteries) 
or had history of stroke (diagnosis based on clinical features and CT). 
The remaining 161 diabetic patients were free of any complications. 
Clinical and laboratory characteristics are shown in Table 1. The 
research has been carried out within an ethical framework, informed 
consents of all participants are documented. 
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Laboratory measurements 
      Venous blood samples were drawn after an overnight fast. 
Plasma glucose, creatinine were measured in central biochemistry 
laboratory. Serum total cholesterol, HDL-cholesterol and triglycerides 
(TG) were measured by automated enzymatic methods on Hitachi 
analyzer, LDL cholestrol was calculated according to Friedwalds 
formula. HbA1c was measured by high-performance liquid 
chromatography.  
      Paraoxonase activity  was determined spectrophotometrically 
[44]. Serum was preincubated with 5x10-6 mol/l eserine (Sigma- 
Aldrich) for 10 minutes at room temperature to inhibit serum 
butyrylcholinesterase activity, which is markedly elevated in diabetes 
and interferes with determination of paraoxonase activity. Preliminary 
experiments showed that these conditions completely inhibited 
butyrylcholinesterase without any effects on paraoxonase activity. 
Paraoxonase activity was measured by adding 6,6 µl of serum to 1 ml 
Tris/HCl buffer (100 mmol/L, pH 8.0, Sigma-Aldrich) containing 2 
mmol/l CaCl2 and 5.5 mmol/l paraoxon (O,O-diethyl-O-p-
nitrophenylphosphate; Sigma –Aldrich). The rate of  p-nitrophenol 
generation was determined on spectrophotometer Spectronic at 405 
nm and 25°C. PON1 activity was expressed in nmol/mi n/ml. 
      Superoxid dismutase  activity  was determined also 
spectrophotometrically by xanthine/xanthine oxidase system. The 
method is based on the reaction described by McCord and Fridovich 
[45]. SOD activity was expressed in international units (U). 
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DNA analysis 
      Blood was extracted from the peripheral blood (5-10 ml) and 
genomic DNA was prepared from leucocytes (minimal amount of 
leucocytes was 3,5 . 109 /l ) by sodium dodecylsulphate (SDS) lysis 
by ammonium acetate extraction and ethanol precipitation. 
Determination of the PON1, SOD1, SOD2 and  CAT polymorphisms 
was achieved by PCR-RFLP analysis. Details are shown in Tab.2. 
Digested PCR products were visualised by UV transillumination 
following ethidium bromide staining and migration compared against 
DNA ladder and a positive RFLP control sample. 3% agarose gel 
including 0,5 µg/ml ethidium bromide, 10 µl of molecular markers (two 
different types used simultaneously) and 20 µl of amplicon for the 
other wells were applied for electrophoresis. 0,5xTBE buffer (pH 8) 
including 0,5 µl/ml ethidium bromide was used. Running conditions 
were 100 V, 40 mA and 140 min. Information about all SNPs and 
SNP ID were obtained from the NCBI homepage and all SNPs have 
been validated by multiple, independent submissions to the refSNP 
cluster. The genotyping success rate was 95.0% (range 91.1 to 
98.4%). Water control, internal controls and previously genotyped 
samples were included in each plate to ensure accuracy of 
genotyping. Positive and negative controls were used in each 
genotyping assay.  To ensure quality control, the genotyping analysis 
was performed "blind" with respect to case/control status. About 10% 
of the samples were randomly selected to be genotyped again by a 
different investigator, who was also unaware of the status of studied 
subjects. The results were concordant. The polymorphisms were also 
examined by PCR and RFLP analysis described previously 
[46,47,48]. 
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Statistical analysis 
      Age, BMI and duration of diabetes were compared between 
studied groups using Student's t-test. Statistical analyses of 
frequency counts were performed using the Chi-square (χ2) test. 
Comparison of continuous variables (HbA1c) among the SOD 
genotypes was performed with the use of ANOVA. A logistic regression 
analysis was performed to evaluate the interaction between the 
genotypes and other variables in relation to the prevalence of macro- 
or  microangiopathy. In this analysis, the dependent variable was the 
presence or absence of vascular complication. Independent variables 
included in this analysis were BMI, age, present HbA1c level, type of 
diabetes, duration of diabetes, SOD activity and  genotype. P values 
<0.05 were considered as significant. The laboratory data are 
expressed as means ± SD. The analysis was performed using 
programme Statistica 6.0 (StatSoft). Testing for deviation from Hardy-
Weinberg equilibrium (HWE) was performed and all the observed 
genotype frequencies were in agreement with HWE. 
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Results 
Serum PON1 activity 
      Serum PON1 activity was significantly decreased in T1DM 
(110±68 nmol/min/ml; 95% CI: 96-120 nmol/min/l) and in T2DM 
patients (118±69 nmol/min/l; 95% CI:111-127 nmol/min/l) compared 
to the control subjects (203±58 nmol/min/ml; 95%CI:190-226 
nmol/l/min ), both p< 0,01. No gender or age influence on its activity 
was found in diabetic or healthy subjects. The lower serum PON1 
activity was found in patients (T1 and T2) with macrovascular 
(109±71 nmol/min/ml; 95%CI: 91-113 nmol/min/l) than in those with 
microvascular complications (119±69 nmol/min/ml; 95%CI: 108-128 
nmol/min/ml, p<0,05 ).  
 
The effect of the L55M PON 1 polymorphism on PON 1 activity in 
healthy subjects and diabetic patients 
      The LL (Leu/Leu) genotype was the most common in healthy 
subjects followed by the LM (Leu/Met) genotype, whereas the LM 
was more common than  the LL genotype in T1DM and T2DM 
patients (Tab. 3). Significant differences between the allele and 
genotype frequencies (Tab.3) for the PON1 55 polymorphism was 
observed in T1DM as compared to controls (L: 0.69 vs 0.52, p<0.01; 
M: 0.31 vs. 0.48, p<0.05) and similarly in T2DM (L: 0.58 vs. 0.52; M:  
0.42 vs 0.48, p<0.05). The 55 gene polymorphism was related to 
PON1 serum activity. Higher activities were found in LL than in MM 
genotypes of diabetic patients but not in control subjects (Tab. 3).  
 
Relationship between the PON 1 Q192R  polymorphism and PON 
1 activity in the controls and DM population 
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      The QQ genotype (Gln/Gln) was the most common in both T1DM 
and T2DM patients as well as in healthy subjects whereas the RR 
genotype was the rarest one (Tab. 3). The allele frequency of the 
PON1 192 polymorphisms was significantly different in healthy 
persons compared to T1DM and T2DM patients (Q: 0.54 (controls) 
vs. 0.81 (T1) or 0.85 (T2), p<0.05, R: 0.46 (controls) vs. 0.19 (T1) or 
0.15 (T2), p<0.05) (Fig. 1). 
In both groups of diabetic patients PON1 activity was the highest in 
the RR genotype and the lowest in the QQ genotype whereas no 
differences were found in healthy persons (Tab. 3.). 
 
Relationship between the PON 1 promotor  polymorphisms  and 
PON 1 activity in the controls and DM population 
      We found no statistically significant differences between 
frequencies in alleles of  both promotor SNPs between DM patients 
and healthy subjects (Tab.3). PON1 activity, as well as diabetes 
control, were not influenced by polymorphisms in the promotor region 
(Tab. 4). Glycated haemoglobin (%) was 6,69±1,34; 95% CI: 6,19-
7,02 in C allele carriers vs. 6,61±1,45; 95% CI: 6,29-7,10 in T allele 
carriers with p=0,261 in -107C/T polymorphism and 6,70±1,69; 
95%CI: 6,53-7,12  in G allele carriers vs. 6,58±1,55; 95%CI: 6,28-
7,07 in C allele carriers with p=0,326 in -907 G/C polymorphism.  
 
The association of PON 1 polymorphisms and PON1 activity  
with diabetes control and vascular complications 
      In T1DM and T2DM patients diabetes control expressed by 
glycated haemoglobin values was poorer in MM genotype (7,10±1,51; 
95%CI: 6,42-7,91 in T1DM and 7,29±1,49; 95%CI: 6,70-8,46 in 
T2DM) than in LL genotype (6,39±1,1; 95%CI: 5,7-7,0 in T1DM and 
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6,71±1,21; 95%CI: 5,73-6,99) with p<0,05 and similarly in QQ 
genotype (6,9±1,4; 95%CI: 5,53-7,35 in T1DM and 6,9±1,4; 95%CI: 
5,58-7,09 in T2DM) than in RR genotype (5,95±1,51; 95%CI: 5,39-
7,14 in T1DM and 6,1±1,51; 95%CI: 5,70-7,35 in T2DM) with p<0,05. 
(Fig. 2). The patients with LM and QR genotypes had intermediate 
diabetes control. 
Significantly different genotype frequencies of both SNPs in coding 
region of gene were found in diabetic patiens (T1DM and T2DM) with 
macroangiopathy (ma+). When compared these with LL vs.(LM and 
LM) genotypes: OR (odds ratio)  3.07; 95% CI 1.55-7.44 with p<0,01 
and  QQ vs. (QR and RR) genotypes: OR 0,62; 95%CI  0,38-0,88 
with p<0,01. No differences in genotype frequencies were associated 
with microangiopathy (mi+). When compared these with LL genotype 
vs. (LM and MM): OR 95%, OR 0,92; CI 0.58-1.62 with p= 0.843 and 
QQ genotype vs. (QR and RR) genotypes: OR 0,96 95%; CI 0.62-
1.78 with p= 0.752.  
      Macroangiopathy was associated with significantly higher 
frequency of  M allele (0,59 in ma+ group vs. 0,44 in group without 
complications, p≤0,01) and lower frequency of R alelle (0,12 in ma+ 
group vs. 0,19 in group without vascular complications, p≤0,05) 
whereas no such distrubution was found in microangiopathy (M allele 
was 0,47 in mi+ group vs. 0,44 in group without complications with 
p=0,218 and R allele was 0,18 in mi+ group vs. 0,19 in group without 
complications with p= 0,542).  Frequencies of genotypes ranged 
according to presence of vascular complications in both types of 
diabetes mellitus are showed  in Figure 3. 
      We found no statistically significant association of promotor 
polymorphisms with macro- or microangiopathy (Tab. 4). 
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We found also negative correlation between serum paraoxonase 
activity (PON1) in both types of diabetes mellitus and the values of 
glycated haemoglobin (HbA1c %) (Fig. 4), as well as the presence of 
vascular complications in both types of diabetes (Fig.5). 
       
SOD activity 
      Serum SOD activity was significantly decreased in T1DM 
(0,75±0,18 U; 95% CI: 0,72, 0,79 ) and in T2DM patients (0,71±0,33; 
95% CI: 0,67, 0,74) compared to the control subjects (1,67±0,33, 
95% CI: 1,61, 1,72), both p< 0,01. Differences between T1DM and 
T2DM in SOD activity were not found statistically significant (p=0,14). 
No gender or age influence on its activity was found in diabetic 
patients or healthy subjects. Difference in SOD activity between 
diabetic patients and healthy subjects is probably accountable not 
only by genotype background but also by various effects in terms of 
diabetes, e.g. enzyme glycation.The lower serum SOD activity was 
found in patients (T1DM and T2DM) with macrovascular 
complications (0,51±0,31 U; 95%CI: 0,43, 0,58) than in those with 
microvascular complications (0,74±0,16 U; 95%CI: 0,71, 0,76), 
p<0,01 or without any vascular complications (0,76± 0,34 U;95%CI: 
0,71, 0,81), p< 0,05.   
 
The effect of the SOD1 +35A/C  polymorphism on SOD  activity 
in healthy subjects and diabetic patients with DM 
      The AA  genotype was the most common observed in the healthy 
subjects followed by the AC genotype, whereas the AC was more 
common than  the AA genotype in T1DM and T2DM patients (Tab. 3). 
Significant differences between the allele and genotype frequencies 
for the SOD1 +35A/C polymorphism was observed in T1DM as 
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compared to controls (A: 0.69 vs 0.52, p<0.01; C: 0.31 vs. 0.48, 
p<0.05) and similarly in T2DM (A: 0.58 vs. 0.52; C:  0.42 vs 0.48, 
p<0.05). This SNP was related to SOD serum activity.  Higher 
activities were found in AA than in CC genotypes of diabetic patients 
(Tab. 3).  Statistical analysis (analysis of variance) showed significant 
trend towards possible association of AA genotype with higher activity 
(P (trend) = 0.029). Diabetic and healthy subjects have been pooled 
together as one group in the study of association between SOD 
activity and genotypes to improve statistical power of analysis. 
Differences among these subjects in age, duration of diabetes, 
presence of other co-morbidities were included.  
 
Relationship between the SOD2 Ala16Val (C/T)  polymorphism 
and SOD activity in healthy subjects and patients with DM 
      The TT genotype (Val/Val) was the most common in both T1DM 
and T2DM patients, CT genotype was the most common in healthy 
subjects whereas the CC genotype (Ala/Ala) was the rarest one in all 
groups (Tab. 3). The allele frequency of the SOD2 polymorphisms 
was significantly different in healthy persons compared to T1DM and 
T2DM patients (T allele (Val): 0.54 (controls) vs. 0.81 (T1) or 0.85 
(T2), p<0.05 and C allele (Ala): 0.46 (controls) vs. 0.19 (T1) or 0.15 
(T2), p<0.05  (Fig. 6).  In all groups of diabetic patients SOD activity 
was the highest in the CC genotype (Ala/Ala) and the lowest in the TT 
genotype (Val/Val) (Tab. 3.). 
 
CAT  polymorphism in diabetes mellitus 
      We found no statistically significant differences between 
frequencies in alleles of  CAT SNP between diabetic patients and 
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healthy subjects (p=0,294). Control of diabetes was not influenced by 
polymorphisms in the CAT gene (Tab. 5).  
 
The association of  enzyme activity and polymorphisms in SOD1 
and SOD2 with diabetes control and vascular complications of 
diabetes mellitus 
      Diabetes control expressed by glycated haemoglobin values was 
poorer in TT genotype (Val/Val) of SOD2 (7,10±1,51; 95%CI: 6,42-
7,91 in T1DM and 7,29±1,49; 95%CI: 6,70-8,46 in T2DM) than in CC 
genotype (Ala/Ala) of SOD2 (6,39±1,1; 95%CI: 5,7-7,0 in T1DM and 
6,71±1,21; 95%CI: 5,73-6,99 in T2DM), p<0,05.  
      No effect of SNP in SOD1 gene on diabetes control was found. 
Glycated haemoglobin was 6,7±1,4; 95%CI: 5,41-6,23 in T1DM and 
6,9±1,4; 95%CI: 5,48-6,09 in T2DM, both in AA genotype of SOD1 
gene and 6,59±1,22, 95%CI: 5,08-6,24 in T1DM and 6,61±1,51; 
95%CI: 5,02-6,05 in T2DM, both in CC genotype of SOD1 gene, with 
p=0,124.  
      Similar findings were made in CAT gene. Glycated haemoglobin 
was 6,14±1,11; 95% CI: 6,06-6,57 in T1DM and 6,50±0,85; 95%CI: 
6,32-7,25 in T2DM, both in AA genotype of CAT and 6,19±1,32, 95% 
CI: 6,09-6,60 in T1DM and 6,61±0,54; 95%CI: 6,45-7,05 in T2DM, 
both in TT genotype of CAT gene, with p=0,249.  
      Significantly different genotype frequencies of SNPs were found 
in diabetic patiens (T1DM and T2DM) with macroangiopathy (MA+) in 
SOD1 and SOD2 genes. When compared these with CC genotype 
vs. AC and AA genotypes of SOD1: OR (odds ratio) was 1.73; 95% 
CI 1.45-5.37 with p<0,05,  CC genotype (Ala/Ala)  vs. CT (Ala/Val) 
and TT (Val/Val) genotypes of SOD2: OR was 0,62; 95%CI  0,58-
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0,90 with p<0,01. When compared  AA genotype vs. AT and TT 
genotypes of CAT: OR was 1.05; 95%CI 0,78-1,13, p=0,851.         
      Macroangiopathy was associated with significantly higher 
frequency of  C allele in SOD1 gene (0,58 in MA group vs. 0,42 in DM 
group without complications, p<0,01), lower frequency of C alelle 
(Ala) in SOD2 gene (0,28 in MA group vs. 0,39 in DM group without 
vascular complications, p<0,05) whereas no such distribution was 
found in CAT gene, p=0,594. 
      No differences in genotype frequencies were associated with 
microangiopathy (MI+). When compared these with CC genotype vs. 
AC and AA genotypes in SOD1:  OR was 0,91; 95%CI 0.74-1.32 with 
p= 0.783, CC genotype (Ala/Ala) vs. CT (Ala/Val) and TT (Val/Val) 
genotypes in SOD2: OR was 0,96; 95% CI 0.52-1.38 with p= 0.852 
and AA genotype vs. AT and TT genotypes in CAT: OR 1,04 95%; CI 
0,37-1,26 with p=0,814. No statistically significant differences in allele 
frequencies were found in all SNPs of the studied genes in the 
patients with microangiopathy when compared with patients without 
vascular complications (C allele in SOD1 was 0,47 in MI group vs. 
0,42 in DM group without complications, p=0,118, T allele in SOD2 
was 0,35 in MI group vs. 0,39 in DM group without complications, p= 
0,242). Frequencies of genotypes ranged according to presence of 
vascular complications in both types of diabetes mellitus are showed  
in Figure 6. 
      We found negative correlation between serum superoxide 
dismutase activity (SOD) in both types of diabetes mellitus and the 
values of glycated haemoglobin (HbA1c %) (Fig. 7), as well as the 
presence of vascular complications in both types of diabetes (Fig.8). 
      Association of the PON1 polymorphism in coding and promotor 
region, SOD1, SOD2 and CAT polymorphisms, BMI, age, duration of 
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diabetes, sex, type of diabetes, PON1 and SOD activity as 
independent variables with the presence of  micro- or 
macroangiopathy as dependent variable was performed using a 
logistic regression model. This analysis indicated that PON1 L55M, 
Q192R, SOD1 and SOD2 genotypes are significantly associated with 
macroangiopathy. Another variables significantly associated (p<0,05) 
with angiopathy were HbA1c, PON1 activity, SOD activity and 
duration of diabetes. No independent contribution has been 
demonstrated for age, sex, BMI and the type of diabetes (Tab. 6).  
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Discussion 
      In present study we found significantly different proportion of 
alelle distribution for two coding region but not for promotor sequence 
of PON1 gene in Type 1 and Type 2 diabetic patients as compared 
with healthy subjects. Our findings of L55M and Q192R 
polymorphisms in diabetes are in agreement with previous 
observations of other authors [49]. We confirmed that serum PON1 
activity is significantly reduced in diabetic patients [50]. The presence 
of PON1-55 MM and PON1-192 QQ genotypes was associated with 
poorer diabetes control than LL and RR genotypes. Finally, 
macroangiopathy was associated with significantly higher frequency 
of  M allele and lower of R alelle whereas no such distrubution was 
found in microangiopathy. 
      Peroxidation of low density lipoproteins (LDL) plays a central role 
in atherogenesis [51]. Enzymes  associated with HDL particles, 
including paraoxonase 1, platelet-activating factor acyltransferase 
and lecitin-cholesterol acyltransferase (LCAT), can cleave oxidised 
lipids from LDL. High-density lipoproteins (HDL) diminish the 
accumulation of lipid peroxides in LDL mainly due to paraoxonase 
activity. In vitro PON 1  protects LDL from the copper-induced 
generation of oxidation products, particularly LDL-conjugated dienes. 
Associations between PON-1 gene polymorphisms and 
cardiovascular disease could be therefore influenced by these 
enzyme-protective effects in vivo.  
      PON1 gene polymorphisms may influence variability of the 
enzyme activity and some cross-sectional and case-control studies 
have described an association between cardiovascular disease or 
cardiovascular events and PON1 gene polymorphisms in diabetes 
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mellitus and non-diabetic subjects [52]. The low PON1 activity 
decreases ability to prevent lipid-peroxide formation with consequent 
acceleration of the oxidative stress. Overproduction of the reactive 
oxygen species in diabetic patients may be due to chronic 
hyperglycemia, hyperinsulinaemia, elevated free fatty acids (FFA) 
and dyslipidemia [51]. Plasma lipids also modifies composition, 
function and concentration of the HDL. Elevated plasma triglyceride-
rich lipoproteins may substitute cholesterolesters (CE) in HDL by 
driving cholesterol ester transfer protein (CETP) with subsequent 
HDL depletion of CE.            
      As a result, both the conformation and function of HDL may be 
altered. Glycation of HDL or directly of PON1 in HDL as occurs in 
diabetes may result in detachment of PON1 itself from the HDL and 
PON1 inactivation [50]. The low enzyme activity is caused rather by 
glycation of the PON1 protein than by reduced  synthesis of its 
molecules [53]. PON1 is bound by HDL in lesser extent in diabetic 
patients as compered to healthy persons and its activity is then poorly 
stabilized [54]   
      Our results support an idea that lipid protection against oxidation 
by PON1 may be reduced in diabetic patients because of lower 
enzyme activity. The association of MM and QQ genotypes in two 
tested regions with poorer diabetes control and more decreased 
enzyme activity in macroangiopathy relates to the assumption that L 
and R carriers might be better protected against atherosclerosis. On 
the contrary, in some studies the RR genotype was more prevalent in 
subjects with history of cardiovascular disease than in those without it 
[55,56]. Other authors did not find any relationship of  PON1 Q192R 
polymorphism to cardiovascular disease [57,58].  
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      The strongest candidate for the natural substrate of PON seems 
to be one of the modified LDL phospholipids, an oxidised arachidonic 
acid derivative [59]. Previous observations indicate that the activity of 
PON, measured by non-physiological substrate paraoxon, may be 
adequate to predict its antioxidative properties, which may take part 
in the development of macrovascular complications in diabetes 
mellitus. 
      Large differences between ethnic populations are known in the 
PON1 genotype distribution which may be the reason for differences 
among studies [60].  
      We conclude that the PON1 192 RR and 55 LL genotypes are 
associated with higher PON1 activity than QQ and MM genotypes 
and may be more protective to lipid peroxidation. Moreover, higher 
prevalence of QQ and MM genotypes in diabetes is associated with 
poorer glucose control and therefore advanced non-enzymatic 
glycation as well as greater oxidative stress.  
      Our findings in SOD2 gene are in agreement with previous 
observations of other authors [61]. We also confirmed known fact that 
serum SOD activity is significantly reduced in patients with DM [62]. 
The presence of TT (Val/Val) genotype in SOD2 gene was 
associated with poorer diabetes control in comparison with CT 
(Ala/Val) and CC (Ala/Ala) genotypes.  Macroangiopathy was 
associated with significantly lower frequency of C (Ala) alelle of 
Ala16Val SNP of SOD2 gene. This has not been confirmed by 
another study focused on the role of antioxidative enzymes (including 
SOD2) in determining genetic susceptibility to the coronary artery 
disease in patients with T2DM [63]. Other studies suggest that 
Ala16Val SNP of SOD2 gene is not related to pathogenesis of 
diabetes but is associated with microangiopathy expressed as 
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microalbuminuria [64] or macular edema in patients with T2DM [65]. 
No such distrubution was found in microangiopathy in our study. 
Finally, we found negative correlation between SOD activity in both 
types of diabetes and level of control (expressed by glycated 
haemoglobin) and presence of microangiopathy or macroangiopathy.  
      SNP in the signal sequence of SOD2 (Ala16Val) appears to be a 
minor determinant of carotid atherosclerosis [40. The Ala type of 
SOD2 might have an common alfa-helical structure while the Val type 
might change its conformation to beta-sheet [66]. The Val variant of 
the SOD2 might be present at a lower concentration in the 
mitochondria. The processing study of these 2 leader signals has 
suggested that the basal level of the SOD2 activity might be the 
highest for Ala/Ala genotype (C/C) [66]. Observed positive 
association of macroangiopathy and high levels of glycated 
haemoglobin with the SOD2-Val/Val genotype could be explained, at 
least in part, by the Val izoform of the SOD2. It may lead to decrease 
resistance against ROS produced in the mitochondria and to 
oxidative damage of proteins [67]. The Ala allele of the SOD2 gene is 
more widespread than the Val allele in Caucasian population in 
contrast to Asian populations. 
      Our results are indicative of potential effect of A/C SNP in SOD1 
gene on enzyme activity. It is known that deficiency in SOD1 results 
in increased levels of vascular superoxide and peroxynitrite and 
impaired endothelium-dependent  relaxation in both large arteries and 
microvessels [68] and caused hypertrophy of arteries [69]. 
Macroangiopathy was associated with significantly higher frequency 
of  C allele of +35 A/C SNP of SOD1 gene whereas no such 
distrubution was found in microangiopathy. 
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      We found no statistically significant differences in distribution of 
CAT alleles in studied SNP and no impact of this SNP on the 
presence of vascular complications and the level of glycated 
haemoglobin. Hypocatalasaemic patients were found to have higher 
plasma levels of homocysteine and lower levels of folate [40], 
suggesting these patients are at greater risk for cardiovascular 
diseases. SNPs in the catalase promoter have been identified in a 
Swedish population [70] but their relationship to the vascular disease 
risk has not been determined. A variant within the catalase promoter 
region has been associated with essential arterial hypertension in an 
isolated Chinese population [71]. T1DM susceptibility locus on the 
chromosome 11p13 near to the catalase gene supports the idea of 
CAT gene may play a role in DM [72]. On the other side another 
authors found no evidence for a major effect of CAT SNPs  on T1DM 
susceptibility in two large sample collections [73].      
      The study inconsistency in the association between genotypes 
and DM or cardiovascular disease is partly due to the limits of cross-
sectional case-control studies because selection bias have to be 
considered and the statistical analysis might have failed to 
demonstrate any significant differences.  
     Genetic background may be at least partly associated with 
diabetes control and consequently enzyme activities protecting 
against oxidative stress. Vascular disorders like atherosclerosis are 
then the results of combined genetic and metabolic changes. 
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Conclusions 
 
• enzyme activity of PON1 was significantly decreased in patients 
with both types of diabetes mellitus in comparison with control 
subjects. 
• allele and genotype frequency of  L55M a Q192R in the coding 
region of PON1 gene differed significantly between patients with 
diabetes mellitus and healthy subjects. 
• we found no such distribution of allele and genotype frequency of 
polymorphisms in the promotor region of PON1 gene in both 
compared groups (diabetic and nondiabetic). 
•  patients with both types of diabetes had better glycaemic control 
of the disease (expressed by glycated haemoglobin) in the presence 
of LL genotype in L55M SNP and RR genotype in Q192R SNP of 
PON1 gene.  
• the presence of macroangiopathy was significantly associated 
with higher frequency of M allele and lower frequency of R allele.  
• no such distribution has been found in the promoter region of 
PON1 gene according to the presence of macroangiopathy nor level 
of glycaemic control of the disease (expressed by glycated 
haemoglobin). 
• we found no association between microangiopathy and studied 
polymorphisms both in coding and promoter region of PON1 gene. 
• enzyme activity of PON1 correlated negativelly with the values of 
glycated haemoglobin in patients with diabetes mellitus. 
• enzyme activity of PON1 was significantly decreased in patients 
with vascular complications of diabetes mellitus.  
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• enzyme activity of superoxide dismutase has been found 
significantly lower in patients with diabetes mellitus in comparison 
with healthy subjects. Moreover, patients with macroangiopathy had 
SOD activity lower than those with microangiopathy. 
• allele and genotype frequency differed statictically significantly 
when compared patients with both types of diabetes mellitus with 
control subjects in +35A/C SNP in SOD1 gene and Ala16Val in SOD2 
gene. No such difference has been found in -21A/T in CAT gene. 
• patients with both types of diabetes mellitus have better long-
term glycaemic control of the disease (expressed by glycated 
haemoglobin) in the presence of CC (Ala/Ala) genotype in SOD2 
gene. 
• no such distribution has been found in the studied SNPs of 
SOD1 a CAT genes according to the level of glycaemic control of the 
disease (expressed by glycated haemoglobin). 
• the presence of macroangiopathy was significantly associated 
with higher frequency of C allele of  +35A/C polymorphism in SOD1 
gene and lower frequency of C(Ala) allele of Val16Ala polymorphism 
in SOD2 gene. No such distribution has been found in the CAT gene 
according to the presence of macroangiopathy.  
• we found no association between microangiopathy and studied 
polymorphisms in SOD1, SOD2 and CAT.  
• enzyme activity of SOD correlated negativelly with the values of 
glycated haemoglobin in patients with diabetes mellitus. SOD activity 
was significantly decreased in patients with vascular complications of 
diabetes mellitus.  
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Tables 
 
Table 1     Clinical and laboratory characteristics. 
 
 
 
T1DM P values (a) T2DM Controls P values (b) 
Gender (males/females) 58/62 0,602 156/150 93/87 0,198 
Mean age (years) 40±12 0,022 57±15 39±9 0,043 
Duration of DM (years) 18±9 0,853 17±8 0 - 
BMI (kg/m2) 22±4 0,03 30±5 21±5 0,027 
Systolic BP (mmHg) 120±10 0,748 125±25 120±20 0,676 
Diastolic BP (mmHg) 60±20 0,521 70±30 70±15 0,621 
Microvascular complications(n) 40 0,048 159 0 - 
Macrovascular complications(n) 14 0,016 52 0 - 
FPG (mmol/l) 6,60±1,35 
 
0,058 7,82±2,29 4,95±0,76 0,009 
HbA1c (%) 6,1±1,9 0,321 6,7±1,8 0 - 
GFR (MDRD)  (ml/s/1,73m 2 ) 1,23±0,35 0,179 1,09±0,28 1,35±0,22 0,041 
Total cholesterol (mmol/l) 4,8±0,5 0,042 5,3±0,7 4,8±0,3 0,205 
HDL-C (mmol/l) 1,55±0,35 0,216 1,31±0,32 1,75±0,66 0,325 
LDL-C (mmol/l) 3,22±0,53 0,116 3,57±0,81 3,10±0,74 0,234 
Triglycerides (mmol/l) 1,31±0,30 0,031 1,99±0,79 1,23±0,48 0,038 
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Table 2  Sequences of primers and used restrictases. 
 
 
SNP 
sequence of 
used 
primers 
restrictase restriction 
fragments 
 
5´CTATCCAGAAA
ACACGGTGGGC
C 3´ 
 
SOD1 35 A/C 
 
5´TCTATATTCAA
TCAAATGCTACA
AAAC3´ 
 
 
 
 
HhaI 
 
 
 
 
C allele 71bp 
and 207 bp 
 
 
A allele 278 bp 
 
5´GCTGTGCTTTC
TCGTCTTCAG 3´ 
 
SOD2 A16V 
(C/T) 
 
 
5´TGGTACTTCTC
CTCGGTGACG3´ 
 
BsaWI C allele 267 bp 
 
T allele 183bp 
and 84bp 
 
5'-
AATCAGAAGGCA
GTCCTCCC-3' 
CAT  -21 A/T 
 
5'-
TCGGGGAGCAC
AGAGTGTAC-3' 
HinfI A allele 203 bp 
and 47bp 
 
T allele 250bp 
 
PON1    
L55M 
5´-
TTGAGGAAAAGC
TCTAGTCCA-3´ 
Hsp92II L allele 384 bp  
 
M allele 282 bp 
and 102 bp 
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5'-
GAAAGACTTAAA
CTGCCAGTCC-3' 
5'-
TTGTTGCTGTGG
GACCTGAG-3' 
PON1 
Q192R 
5'-
AATCCTTCTGCC
ACCACTCG-3' 
AlwI Q allele 150 bp 
 
R allele 89 bp 
and 61 bp 
5´-
AGTTTAATTATGT
ATTTTCGCGGAC
CCGGCGGGGAG
GAG-3' 
PON1 -107 
C/T 
5'-
GGGGCTCGTGG
AGCTGGCAG-3' 
BsrBI C allele 210 bp 
 
T allele 95 bp 
and 115 bp 
5'-
CAATGTGAGGCC
AAAGAAGC-3' 
PON1 -907 
G/C 
5'-
CCTTTACCCCTC
ATTCCCTGAGGT
GCCTCTGTACAC
CCATAT-3' 
NdeI G allele 314 bp 
 
C allele 84 bp 
and 230 bp 
 
 
 
 
 
 
 
 
 31 
Table 3 The occurrence of genotypes in studied 
polymorphisms. 
 
  LL LM MM QQ QR RR 
n (%) 23 (27) 43 (50) 19 (22)* 49 (57) 22 (26) 14 (17)* 
T1DM 
PON1 
act 122±44¶ 119±40 103±48¶ 113±32¶ 115±48 121±33¶ 
n (%) 69 (28) 124 (51) 53 (21)* 156 (63) 59 (24) 31 (13)* 
T2DM 
PON1 
act 119±34¶ 114±48 108±39¶ 106±48¶ 114±34 118±31¶ 
n (%) 76 (70) 29 (26) 5 (4)* 39 (36) 36 (32) 35 (31)* 
Controls 
PON1 
act 206±48 205±52 202±48 202±43 204±31 204±29 
  CC CT TT GG GC CC 
n (%) 26 (30) 42 (49) 18 (21) 42 (49) 36 (42) 8 (9) 
T1DM 
PON1 
act 115±34 119±40 118±36 113±38 120±30 118±34 
n (%) 71 (29) 123 (50) 52 (21) 117 (48) 104 (42) 25 (9) 
T2DM 
PON1 
act 112±30 114±32 113±39 114±31 118±34 115±38 
n (%) 37 (33) 55 (50) 18 (17) 57 (51) 44 (40) 9 (9) 
Controls 
PON1 
act 199±42 205±38 202±46 206±40 200±32 203±38 
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The occurrence of genotypes in studied polymorphisms among T1, T2 
diabetic patiens and healthy subjects (controls), serum superoxide dismutase 
activity separated according to the genotypes in compared groups (AA/AC/CC 
in SOD1 gene, TT/CT/CC in SOD2 gene, AA/AT/TT in CAT gene). Data are 
expressed in mean±SD, n means number of cases, brackets mean genotype 
frequencies (allele frequencies and differences among them are mentioned in 
text),  PON1 act, resp. SOD act means enzyme activity in  nmol/min/ml, resp. 
U.* means differences between genotype frequencies MM (L55M) or RR 
(Q192R) in T1 or T2 DM vs. control subjects with p≤ 0,05. ¶ means 
  AA AC CC TT (Val/Val) 
CT 
(Ala/Val) 
CC 
(Ala/Ala) 
n (%) 58 (48) 50 (42) 12 (10) 79 (66) 36 (30) 5 (4) 
T1DM 
SOD act 
(U) 
0,76±0,1
5 
0,74±0,1
3 
0,73±0,1
9 
0,73±0,1
4 
0,74±0,2
3 
0,77±0,1
8 
n (%) 104 (34) 147(48) 55(18) 220(72) 80(26) 6 (2) 
T2DM 
SOD act 
(U) 
0,73±0,2
9 
0,72±0,3
6 
0,70±0,3
1 
0,72±0,2
8 
0,72±0,1
9 
0,75±0,1
5 
n (%) 49 (27) 90 (50) 41(23) 52(29) 90 (50) 38(21) 
Controls 
SOD act 
(U) 
1,66±0,3
1 
1,67±0,3
5 
1,66±0,2
8 
1,58±0,2
8 
1,60±0,3
5 
1,63±0,0
8 
  AA AT TT    
T1DM n (%) 48(40) 53 (44) 19(16)    
T2DM n (%) 110(36) 147(48) 49(16)    
Controls n (%) 67(37) 86(48) 27 (15)    
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differences between PON1 activity in LL vs. MM or QQ vs. RR genotype in T1 
and T2 DM with p≤ 0.05. 
 
Table 4  Genotype frequencies of promotor 
polymorphisms of PON1 gene. 
 
Genotype MA+ MI+ MA-MI- HbA1c 
CC 0,27 0,26 0,24 6,62±1,35 
CT 0,49 0,49 0,49 6,74±1,30 
TT 0,23 0,24 0,26 6,58±1,12 
GG 0,39 0,36 0,38 6,77±1,39 
GC 0,46 0,48 0,48 6,58±1,46 
CC 0,15 0,16 0,14 6,61±1,32 
 
Genotype frequencies of promotor polymorphisms of PON1 gene according to 
the presence of vascular complications in patients with diabetes mellitus. MA+ 
means presence of macroangiopathy, MI- means presence of 
microangiopathy, MA-MI- group involves patients with no vascular 
complications. HbA1c is glycated haemoglobin (%) marked as mean±SD. 
 
Table 5 Genotype frequencies in CAT gene according to 
presence of vascular complications and values of 
glycated haemoglobin according to  the genotype. 
 
 
Genotype MA+ MI+ MA-MI- HbA1c 
AA 0,28 0,32 0,34 6,28±1,25 
AT 0,50 0,49 0,49 6,35±1,10 
TT 0,22 0,19 0,17 6,32±1,22 
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Table 6 
 
 
 
 
Variable p (MA) OR; 95%CI (MA) p (MI) OR; 95%CI (MI) 
L55M genotype 0,005 3.11; 1,33-8,86 0,813 0,92; 0,49-1,76 
Q192R genotype 0,028 0,51; 0,27-0,98 0,662 0,94; 0.45-1.65 
-107  C/T 0,345 0,94; 0,86-1,08 0,565 0,78; 0,56-1,08 
- 907 G/C 0,357 0,92; 0,76-1,14 0,61 0,90; 0,78-1,12 
PON1 activity 0,035 0,48; 0,25-0,84 0,042 0,52; 0,34-0,82 
SOD1 35 A/C 0,048 1,73; 1,45-5,37 0,783 0,91; 0,74-1,32 
SOD2  A16V 0,009 0,62; 0,58-0,90 0,852 0,96; 0.52-1.38 
CAT -21 A/T 0,851 1,05; 0,78-1,13 0,814 1,04; 0,37-1,26 
SOD activity 0,040 0,48; 0,25-0,9 0,048 0,62; 0,44-0,91 
Type of diabetes 0,084 
 
0,96; 0,89-1,65 0,079 0,88; 0,73-1,17 
Present HbA1c 0,032 1,35; 1,22-1,57 0,025 1,56; 1,22-1,91 
BMI 0,397 0,96; 0,91-1,08 0,452 0,88; 0,77-1,04 
Duration of diabetes 0,025 1,91; 1,37-4,12 0,032 2,01; 1,80-5,31 
Sex 0,66 0,99; 0,89-1,23 0,83 0,98; 0,88-1,22 
Age 0,324 0,93; 0,59-1,34 0,452 0,96; 0,72-1,28 
Type of diabetes 0,034 1,96; 1,79-2,65 0,049 1,98; 1,63-2,13 
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Figures 
Figure 1 
 
 
The frequencies of alleles in L55M and Q192R polymorphisms in 
diabetic patiens and healthy subjects. Statistically significant 
differences between T1DM vs. control subjects are expressed by + 
with p<0,05,  between T2DM vs. control subjects are expressed by * 
with p<0.05. 
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Figure 2 
 
 
 
Box diagram demonstrates glycated hemoglobin values (HbA1c %) in 
subgroups of Type 1 and Type 2 diabetic patiens distinquished 
according to L55M and Q192R genotypes. Statistically significant 
differences between LL vs. MM genotype in L55M polymorphism are 
expressed by *  with p<0.05 and between QQ vs. RR genotype in 
Q192R polymorhism are expressed by +  with p<0.05.   
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Figure 3 
 
 
 
 
Distribution of genotypes in PON1 gene in both types of diabetes 
mellitus according to presence macro-(MA+) or microangiopathy (MI-) 
or no complications (MA-MI-). Explanation of results is mentioned in 
the text. 
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Figure 4 
 
 
 
 
Data correlation between the values of glycated haemoglobin (HbA1c 
%) and serum paraoxonase activity (PON1) in both types of diabetes 
mellitus. The correlation coeficients (Spearman) are r1= -0,37 
(T1DM), r2= -0,13 (T2DM) with p ≤ 0,05 . Dotted lines mean 95% 
confidence intervals. 
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Figure 5 
 
 
Cross-correlation between the presence of vascular complications in 
diabetic patients and the level of serum paraoxonase activity. The 
correlation coeficients are r1=-0,27 (T1DM), r2= -0,25 (T2DM) with 
p≤0,05. Dotted lines mean 95% confidence intervals. 
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Figure 6 
 
 
Distribution of genotypes in SOD1 (A/C allele) and SOD2 (C/T allele, 
Ala/Val)  in both types of diabetes mellitus according to presence of 
macroangiopathy (MA+) or microangiopathy (MI+) or no 
complications (MA-MI-). Explanation of results is mentioned in the 
text. 
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Figure 7 
 
 
 
Data correlation between the values of glycated haemoglobin (HbA1c 
%) and serum superoxide dismutase activity (SOD) in both types of 
diabetes mellitus. The correlation coeficients (Spearman) are r1= -
0,41 (T1DM), r2= -0,23 (T2DM) with p <0,05 . Dotted lines mean 95% 
confidence intervals. 
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Figure 8 
 
 
 
 
Cross-correlation between the presence of vascular complications in 
diabetic patients and the level of serum superoxide dismutase 
activity. The correlation coeficients (Spearman) are r1= -0,29 (T1DM), 
r2= -0,28 (T2DM) with p<0,05. Dotted lines mean 95% confidence 
intervals. 
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